Posters/Publications

paper

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020

Date - 07/2020

oral

FASN inhibitor TVB-2640 in NASH

NASH-TAG

Date - 01/2020

poster

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO

Date - 06/2019

poster

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

San Antonio Breast Cancer Symposium

Date - 12/2018

poster

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

ObesityWeek

Date - 11/2018

poster

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

AASLD

Date - 11/2018

poster

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Date - 11/2018

poster

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD

Date - 01/2018

poster

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

AASLD

Date - 10/2017

poster

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

AASLD

Date - 10/2017

Posters/Publications

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

FASN inhibitor TVB-2640 in NASH

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

Site map

Contact us